Autolus Therapeutics 7.25M share Spot Secondary priced at $11.00 » 05:3501/2301/23/20
The deal priced at the…
The deal priced at the bottom of the $11.00-$11.50 range. JPMorgan and Jefferies acted as joint book running managers for the offering.
Autolus Therapeutics announces offering of 7.25M ADSs » 16:4201/2201/22/20
Autolus Therapeutics announced that it has commenced an offering of up to 7.25M American Depositary Shares, or ADSs, representing 7.25M ordinary shares in an underwritten public offering in the United States. J.P. Morgan Securities and Jefferies are acting as joint book-running managers for the offering. William Blair & Company is acting as lead manager. H.C. Wainwright is acting as co-manager.
|Over a week ago|
Autolus Therapeutics expects to start Phas 1 trial of AUTO1NG in 1H20 » 07:4401/1301/13/20
Autolus Therapeutics is…
Autolus Therapeutics is presenting at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020 at 5:00 pm Pacific Time where Christian Itin, the chairman and chief executive officer of Autolus, will provide an outlook for 2020. Autolus is advancing its lead program, AUTO1 in relapsed/refractory adult acute lymphoblastic leukemia patients, into a potential pivotal trial in the United Kingdom and the United States. During the year, the company also expects to report further clinical data across several programs at key medical conferences, including AUTO1 in adult ALL, AUTO1 in pediatric ALL, AUTO3 in diffuse large B cell lymphoma and AUTO4 in Peripheral T cell lymphoma. Additionally, Autolus expects to commence a Phase 1 clinical trial of AUTO1NG in pediatric ALL in the first half of 2020, plans for a go/no-go decision on Phase 2 initiation of AUTO3 in DLBCL in the middle of 2020, and expects to initiate two new Phase 1 clinical trials with next generation programs, AUTO6NG across certain solid tumor settings and AUTO8 in multiple myeloma, both in the second half of 2020. Autolus will continue in 2020 to progress additional next generation programs through pre-clinical development and expand its suite of cell programming technologies to include programming modules designed for allogeneic applications. A first novel allogeneic application is expected to enter the clinic in the fourth quarter of 2020.
|Over a month ago|
Roth Capital to hold events » 08:3012/0912/09/19
ARQL, AUTL, BGNE, BLUE, BMY, CC, CRSP, FTSV, JNJ, LLY, LOXO, SGMO
Roth Capital KOL Events…
Roth Capital KOL Events at the 61st ASH Annual Meeting being held in Orlando on December 9.
Autolus Therapeutics to host conference call » 07:1912/0912/09/19
Conference call to…
Conference call to discuss new data showcasing clinical progress of AUTO3 in B cell malignancies will be held on December 9 at 8:30 am. Webcast Link
Autolus announces new data highlighting progress on AUTO3 » 09:2512/0812/08/19
Autolus Therapeutics announced new data highlighting progress on AUTO3, the first-in-human bicistronic CD19 and CD22 CAR, in patients with relapsed/refractory diffuse large B-cell lymphoma and pediatric acute lymphoblastic leukemia. The data were presented at the American Society of Hematology Annual Meeting. In the dose escalation phase, 16 patients were treated, with 4 patients dosed at 50 x 106 cells without pembrolizumab; 11 patients were dosed at escalating doses of AUTO3 with pembrolizumab administered at day 14 as follows: 3 at 50 x 106 cells, 4 at 150 x 106 cells, and 4 at 450 x 106 of AUTO3; and 1 patient was dosed with 450 x 106 cells with pembrolizumab administered 1 day before AUTO3 infusion. Fourteen patients were evaluable at one month. AUTO3 was well-tolerated, with no patients experiencing greater than or equal to Grade 3 cytokine release syndrome with primary infusion and 1 of 14 experiencing Grade 3 neurotoxicity that resolved swiftly with steroids, the compamny said. There were no pembrolizumab immune-related toxicities and the majority of grade 3 or higher adverse events were hematological. Across all tested doses 5 patients achieved a complete response, with 4 of 5 complete responses ongoing, the longest at 18 months. All CRs were achieved without need for steroid or tocilizumab-based management of the patients or ICU level care, it added. Among the 10 CAR T-naive patients, at a median follow-up time of 9.7 months, 9 of 10 patients achieved a complete response, and 8 of 10 achieved complete molecular remission by PCR. Estimated overall survival at 12 months was 100%. There are 2 ongoing patients in complete molecular remission at 12 and 15 months post-AUTO3 infusion, respectively. The most common cause of relapse was due to loss of CAR T-cell persistence. The median persistence of CAR-T cells in blood was 170 days.
Autolus presents new data on T cell therapies in leukemia, lymphoma » 19:2312/0712/07/19
Autolus Therapeutics announced new data highlighting progress on its next-generation programmed T cell therapies to treat patients with acute lymphoblastic leukemia and adults with relapsed/refractory diffuse large B cell lymphoma. Updated results for ALLCAR19, the Phase 1 trial evaluating AUTO1 in adults with recurrent/refractory ALL, were presented by Dr. Claire Roddie. The trial is designed to assess the primary endpoints of safety and feasibility of product generation, as well as other secondary endpoints, including efficacy. The trial enrolled patients with a high tumor burden, who were considered high-risk for experiencing cytokine release syndrome. Product was manufactured for 19 patients; product for 13 of those patients was manufactured using a semi-automated closed process, which will be used for commercial supply. As of the data cut-off date of November 25, 16 patients had received at least one dose of AUTO1. AUTO1 was well tolerated, with no patients experiencing Grade 3 or greater CRS, and 3 of 16 patients, who had high leukemia burden, experiencing Grade 3 neurotoxicity that resolved swiftly with steroids. Of 15 patients evaluable for efficacy, 13 achieved MRD negative CR at 1 month and all patients had ongoing CAR T cell persistence at last follow up. CD19-negative relapse occurred in 22% patients. In the patients dosed with AUTO1 manufactured in the closed process, 9 of 9 achieved MRD negative CR at 1 month and 6 months event free survival, and overall survival in this cohort was 100%.
Autolus Therapeutics, Noile-Immune announce licensing agreement » 06:3411/1311/13/19
Autolus Therapeutics and…
Autolus Therapeutics and Noile-Immune Biotech announced that they have entered into a license agreement whereby Autolus will have the right to develop CAR T cell therapies incorporating Noile-Immune's PRIME technology secreting both IL-7 and CCL19. The PRIME technology is designed to improve proliferation and trafficking into solid tumors of both engineered CAR T cells as well as the patient's own T cells. Through the license agreement with Noile-Immune, Autolus has gained the right to incorporate the PRIME technology in its CAR T cell programs against a limited number of cancer targets. Autolus will make an upfront cash payment and milestone payments to Noile-Immune, and Noile-Immune is also entitled to receive royalties on net sales of resulting products. Additional terms of the agreement were not disclosed.
Autolus Therapeutics reports 'encouraging' pre-clinical results for AUTO6NG » 10:4211/1011/10/19
Autolus Therapeutics presented pre-clinical data on AUTO6NG, the company's next generation GD2-targeting CAR T cell therapy, at the 34th Annual Meeting of the Society for Immunotherapy of Cancer being held November 6-10, in Washington, D.C. "Autolus' growing set of programming modules addresses a range of inhibitory factors within the highly complex and dynamic solid tumor microenvironment. This presentation demonstrates the utility of three modules added to the clinically active and validated AUTO6 GD-2 targeting CAR that not only improve CAR T persistence but also combat the immunosuppressive environment," said Dr. Christian Itin, CEO of Autolus. "Based on these encouraging pre-clinical results, which demonstrate the activity of AUTO6NG, we plan on initiating a clinical study in patients with GD2 positive tumors including refractory/relapsed neuroblastoma in the second half of next year."
Autolus Therapeutics expects cash to provide runway into 2H21 » 07:2711/0711/07/19
Autolus anticipates that…
Autolus anticipates that cash on hand provides a runway into the second half of 2021.